Form 4: MYGN COO Verratti Reports RSU Grant, Tax Withholdings

Myriad Genetics COO Mark Verratti reported the grant of 247,423 restricted stock units and subsequent tax-related share disposals.

Summary

• Mark Verratti, Chief Operating Officer of Myriad Genetics Inc. (MYGN), reported changes in his beneficial ownership.
• On March 12, 2026, Verratti was granted 247,423 time-based restricted stock units (RSUs) at a price of $0.
• These RSUs represent a contingent right to receive one share of common stock each and vest in three equal annual installments beginning on the first anniversary of the grant date.
• Between March 13 and March 15, 2026, Verratti disposed of a total of 29,289 shares of common stock.
• These disposals were shares withheld by Myriad Genetics to satisfy tax withholding obligations related to the vesting of previously granted restricted stock units (both time-based and performance-based).
• The shares withheld for tax purposes were valued at the closing price of $4.66 per share on March 13, 2026.
• Following these transactions, Verratti's beneficial ownership stands at 632,770 shares of common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting ongoing executive compensation and alignment with company performance, with routine tax-related share disposals.

Positives

• Grant of 247,423 restricted stock units to the Chief Operating Officer, aligning management's interests with long-term shareholder value.

Negatives

• Disposal of 29,289 shares for tax withholding purposes, which is a common occurrence upon RSU vesting but reduces the officer's direct share count.

Future Outlook

N/A

Industry Context

StockSavvy.ai notes that insider grants of restricted stock units are a standard component of executive compensation packages in the biotechnology and diagnostics industry, aiming to incentivize long-term performance and align executive interests with shareholder value. The subsequent tax withholdings are also a routine event upon RSU vesting.

Comparison to Industry Standards

• This type of RSU grant and tax withholding is a standard practice for executive compensation across various industries, including biotech.
• Companies like Illumina (ILMN) or Exact Sciences (EXAS) also utilize similar equity compensation structures for their executives to foster long-term commitment and performance alignment.

Related Party Transactions

• Grant of restricted stock units and subsequent tax withholdings are part of the executive compensation structure between Myriad Genetics and its Chief Operating Officer.

Stakeholder Impact

• Shareholders: The grant of RSUs aligns the COO's interests with long-term shareholder value. The tax-related disposals are routine and have minimal impact on overall share float.
• Employees: Reflects the company's ongoing executive compensation practices.

Next Steps

• Vesting of the newly granted 247,423 restricted stock units in three equal annual installments, beginning on the first anniversary of the March 12, 2026 grant date.

Key Dates

Recommendation

The filing details routine executive compensation, including an RSU grant and subsequent tax-related share disposals. These transactions are standard and do not provide new fundamental information to alter an investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Myriad Genetics, MYGN, Mark Verratti, Form 4, Insider Trading, Restricted Stock Units, RSU Grant, Tax Withholding, Beneficial Ownership, Executive Compensation